, HESI Pharmacology V2 Exam 2026/2027: Elsevier Evolve
NCSBN Clinical Judgment Model-Aligned Study Set with
Questions & Rationales - 140 Questions
Section 1: General (Questions 1-140)
1 A patient with chronic kidney disease (eGFR 25 mL/min) is prescribed a medication that is primarily eliminated
by renal excretion. The nurse anticipates which adjustment to the dosing regimen?
A) Increased dose and shortened interval
B) Decreased dose and extended interval
C) Unchanged dose and interval
D) Increased dose with extended interval
Answer: B
Rationale: In chronic kidney disease, renal clearance is reduced, leading to drug accumulation. To avoid toxicity, the
dose should be decreased or the interval extended, or both. Option B correctly reflects this principle.
2 A drug exhibits zero-order elimination kinetics. Which statement best describes the relationship between drug
concentration and elimination rate?
A) Elimination rate is proportional to drug concentration.
B) Elimination rate is constant regardless of concentration.
C) Elimination rate increases with concentration until saturation.
D) Elimination rate is dependent on protein binding.
Answer: B
Rationale: Zero-order kinetics means a constant amount of drug is eliminated per unit time, independent of
concentration. This occurs when metabolic or transport systems are saturated.
3 A patient is receiving a drug that is a weak acid (pKa 4.5). In which compartment would the drug be most
ionized, thus reducing its ability to cross cell membranes?
A) Stomach (pH 1.5)
B) Duodenum (pH 6.0)
C) Blood (pH 7.4)
D) Urine (pH 5.5)
Answer: C
Rationale: For a weak acid, ionization is higher in basic environments. At pH 7.4 (blood), the drug is mostly
ionized, reducing lipid solubility and membrane permeability. In acidic stomach (pH 1.5), it is unionized and more
absorbable.
4 A patient on warfarin develops a subtherapeutic INR after starting a new medication. Which mechanism best
explains this interaction?
A) Cytochrome P450 enzyme induction by the new drug
B) Cytochrome P450 enzyme inhibition by the new drug
C) Displacement of warfarin from albumin binding sites
D) Additive anticoagulant effect
Answer: A
,Rationale: Warfarin is metabolized by CYP enzymes. Enzyme induction increases warfarin metabolism, reducing its
anticoagulant effect and INR. Inhibition would increase effect. Displacement is transient and usually increases
effect initially.
5 A drug has a narrow therapeutic index and is highly protein-bound (99%). Which patient condition would most
likely lead to toxicity upon administration of a standard dose?
A) Hypoalbuminemia
B) Renal impairment
C) Hepatic cirrhosis
D) Obesity
Answer: A
Rationale: Hypoalbuminemia reduces protein binding, increasing the free (active) drug concentration, which can
cause toxicity for highly protein-bound drugs. Renal or hepatic impairment affects elimination, not necessarily free
fraction.
6 A patient experiences a severe hypertensive crisis after ingesting tyramine-rich foods while on a monoamine
oxidase inhibitor (MAOI). Which receptor mechanism underlies this reaction?
A) Increased norepinephrine release from presynaptic neurons
B) Blockade of alpha-1 adrenergic receptors
C) Stimulation of beta-2 adrenergic receptors
D) Inhibition of catechol-O-methyltransferase (COMT)
Answer: A
Rationale: MAOIs inhibit monoamine oxidase, increasing intraneuronal norepinephrine. Tyramine displaces
norepinephrine from vesicles, causing massive release and hypertensive crisis. COMT inhibition is not primarily
involved.
7 A drug acts as a partial agonist at mu-opioid receptors. Which statement accurately describes its clinical effect
compared to a full agonist?
A) It produces greater maximal analgesia but with higher abuse potential.
B) It has a ceiling effect for analgesia and respiratory depression.
C) It has no analgesic effect and is used only for opioid withdrawal.
D) It requires higher doses to achieve the same effect as a full agonist.
Answer: B
Rationale: Partial agonists have lower intrinsic activity, producing a ceiling effect where increasing dose does not
increase response. This limits both analgesia and respiratory depression, making them safer in overdose.
8 A patient is receiving a drug that undergoes extensive first-pass metabolism. Which route of administration
would bypass this effect, resulting in higher systemic bioavailability?
A) Oral
B) Sublingual
C) Rectal
D) Transdermal
Answer: B
Rationale: Sublingual administration allows direct absorption into systemic circulation via the oral mucosa,
bypassing the portal vein and liver. Oral and rectal routes are subject to first-pass metabolism, while transdermal
avoids it but is slower.
, 9 Two drugs are co-administered: Drug A (enzyme inducer) and Drug B (substrate of the same enzyme). What is
the expected effect on the half-life of Drug B?
A) Increased half-life
B) Decreased half-life
C) No change in half-life
D) Half-life becomes dose-dependent
Answer: B
Rationale: Enzyme induction increases metabolism of Drug B, leading to faster clearance and a shorter half-life.
This may reduce Drug B's efficacy. Half-life is independent of dose for first-order kinetics.
10 A patient develops a morbilliform rash and elevated liver enzymes after starting an antiepileptic drug. Genetic
testing reveals a variant in the HLA-B*1502 allele. Which drug is most likely responsible?
A) Phenytoin
B) Carbamazepine
C) Valproic acid
D) Levetiracetam
Answer: B
Rationale: HLA-B*1502 is strongly associated with severe cutaneous adverse reactions (e.g., Stevens-Johnson
syndrome) to carbamazepine in certain ethnic groups. Phenytoin also has HLA associations but with a different
allele.
11 A patient with a history of chronic kidney disease (eGFR 25 mL/min) requires treatment for a newly diagnosed
infection. The provider is considering a fluoroquinolone. Which pharmacokinetic consideration is most critical
when selecting the specific agent within this class?
A) The agent's volume of distribution should be minimized to avoid accumulation in renal tissue.
B) The drug should be primarily hepatically metabolized to reduce dependence on renal clearance.
C) The agent should have a high oral bioavailability to ensure consistent systemic exposure.
D) The drug should be chosen based on its propensity to cause QT prolongation, as this is dose-independent.
Answer: B
Rationale: In severe renal impairment (eGFR <30), fluoroquinolones that are predominantly renally excreted (e.g.,
ciprofloxacin, levofloxacin) require dose adjustment, while those with significant hepatic metabolism (e.g.,
moxifloxacin) are safer. Option A is incorrect because volume of distribution is not directly related to accumulation
risk; renal clearance is key. Option C is irrelevant to renal impairment. Option D is a safety concern but not the
most critical pharmacokinetic factor for drug selection in this context.
12 A researcher is designing a study to compare the efficacy of two antihypertensive drugs. To minimize bias, the
study will be double-blind. Which strategy best ensures that the blinding is maintained throughout the trial?
A) Using identical placebo tablets for both drugs and all participants receive both active drugs in a crossover
design.
B) Encapsulating the active drugs and placebo in identical capsules, and having a third party prepare the
randomization code.
C) Administering the drugs intravenously to avoid differences in taste or appearance.
D) Informing participants of the possible side effects of each drug to enhance reporting accuracy.
Answer: B
Rationale: Double-blind means neither participants nor investigators know treatment allocation. Encapsulating drugs
in identical capsules and using a third-party randomization code preserves blinding. Option A is incorrect because a
crossover design doesn't guarantee blinding (participants might receive both drugs sequentially, potentially
NCSBN Clinical Judgment Model-Aligned Study Set with
Questions & Rationales - 140 Questions
Section 1: General (Questions 1-140)
1 A patient with chronic kidney disease (eGFR 25 mL/min) is prescribed a medication that is primarily eliminated
by renal excretion. The nurse anticipates which adjustment to the dosing regimen?
A) Increased dose and shortened interval
B) Decreased dose and extended interval
C) Unchanged dose and interval
D) Increased dose with extended interval
Answer: B
Rationale: In chronic kidney disease, renal clearance is reduced, leading to drug accumulation. To avoid toxicity, the
dose should be decreased or the interval extended, or both. Option B correctly reflects this principle.
2 A drug exhibits zero-order elimination kinetics. Which statement best describes the relationship between drug
concentration and elimination rate?
A) Elimination rate is proportional to drug concentration.
B) Elimination rate is constant regardless of concentration.
C) Elimination rate increases with concentration until saturation.
D) Elimination rate is dependent on protein binding.
Answer: B
Rationale: Zero-order kinetics means a constant amount of drug is eliminated per unit time, independent of
concentration. This occurs when metabolic or transport systems are saturated.
3 A patient is receiving a drug that is a weak acid (pKa 4.5). In which compartment would the drug be most
ionized, thus reducing its ability to cross cell membranes?
A) Stomach (pH 1.5)
B) Duodenum (pH 6.0)
C) Blood (pH 7.4)
D) Urine (pH 5.5)
Answer: C
Rationale: For a weak acid, ionization is higher in basic environments. At pH 7.4 (blood), the drug is mostly
ionized, reducing lipid solubility and membrane permeability. In acidic stomach (pH 1.5), it is unionized and more
absorbable.
4 A patient on warfarin develops a subtherapeutic INR after starting a new medication. Which mechanism best
explains this interaction?
A) Cytochrome P450 enzyme induction by the new drug
B) Cytochrome P450 enzyme inhibition by the new drug
C) Displacement of warfarin from albumin binding sites
D) Additive anticoagulant effect
Answer: A
,Rationale: Warfarin is metabolized by CYP enzymes. Enzyme induction increases warfarin metabolism, reducing its
anticoagulant effect and INR. Inhibition would increase effect. Displacement is transient and usually increases
effect initially.
5 A drug has a narrow therapeutic index and is highly protein-bound (99%). Which patient condition would most
likely lead to toxicity upon administration of a standard dose?
A) Hypoalbuminemia
B) Renal impairment
C) Hepatic cirrhosis
D) Obesity
Answer: A
Rationale: Hypoalbuminemia reduces protein binding, increasing the free (active) drug concentration, which can
cause toxicity for highly protein-bound drugs. Renal or hepatic impairment affects elimination, not necessarily free
fraction.
6 A patient experiences a severe hypertensive crisis after ingesting tyramine-rich foods while on a monoamine
oxidase inhibitor (MAOI). Which receptor mechanism underlies this reaction?
A) Increased norepinephrine release from presynaptic neurons
B) Blockade of alpha-1 adrenergic receptors
C) Stimulation of beta-2 adrenergic receptors
D) Inhibition of catechol-O-methyltransferase (COMT)
Answer: A
Rationale: MAOIs inhibit monoamine oxidase, increasing intraneuronal norepinephrine. Tyramine displaces
norepinephrine from vesicles, causing massive release and hypertensive crisis. COMT inhibition is not primarily
involved.
7 A drug acts as a partial agonist at mu-opioid receptors. Which statement accurately describes its clinical effect
compared to a full agonist?
A) It produces greater maximal analgesia but with higher abuse potential.
B) It has a ceiling effect for analgesia and respiratory depression.
C) It has no analgesic effect and is used only for opioid withdrawal.
D) It requires higher doses to achieve the same effect as a full agonist.
Answer: B
Rationale: Partial agonists have lower intrinsic activity, producing a ceiling effect where increasing dose does not
increase response. This limits both analgesia and respiratory depression, making them safer in overdose.
8 A patient is receiving a drug that undergoes extensive first-pass metabolism. Which route of administration
would bypass this effect, resulting in higher systemic bioavailability?
A) Oral
B) Sublingual
C) Rectal
D) Transdermal
Answer: B
Rationale: Sublingual administration allows direct absorption into systemic circulation via the oral mucosa,
bypassing the portal vein and liver. Oral and rectal routes are subject to first-pass metabolism, while transdermal
avoids it but is slower.
, 9 Two drugs are co-administered: Drug A (enzyme inducer) and Drug B (substrate of the same enzyme). What is
the expected effect on the half-life of Drug B?
A) Increased half-life
B) Decreased half-life
C) No change in half-life
D) Half-life becomes dose-dependent
Answer: B
Rationale: Enzyme induction increases metabolism of Drug B, leading to faster clearance and a shorter half-life.
This may reduce Drug B's efficacy. Half-life is independent of dose for first-order kinetics.
10 A patient develops a morbilliform rash and elevated liver enzymes after starting an antiepileptic drug. Genetic
testing reveals a variant in the HLA-B*1502 allele. Which drug is most likely responsible?
A) Phenytoin
B) Carbamazepine
C) Valproic acid
D) Levetiracetam
Answer: B
Rationale: HLA-B*1502 is strongly associated with severe cutaneous adverse reactions (e.g., Stevens-Johnson
syndrome) to carbamazepine in certain ethnic groups. Phenytoin also has HLA associations but with a different
allele.
11 A patient with a history of chronic kidney disease (eGFR 25 mL/min) requires treatment for a newly diagnosed
infection. The provider is considering a fluoroquinolone. Which pharmacokinetic consideration is most critical
when selecting the specific agent within this class?
A) The agent's volume of distribution should be minimized to avoid accumulation in renal tissue.
B) The drug should be primarily hepatically metabolized to reduce dependence on renal clearance.
C) The agent should have a high oral bioavailability to ensure consistent systemic exposure.
D) The drug should be chosen based on its propensity to cause QT prolongation, as this is dose-independent.
Answer: B
Rationale: In severe renal impairment (eGFR <30), fluoroquinolones that are predominantly renally excreted (e.g.,
ciprofloxacin, levofloxacin) require dose adjustment, while those with significant hepatic metabolism (e.g.,
moxifloxacin) are safer. Option A is incorrect because volume of distribution is not directly related to accumulation
risk; renal clearance is key. Option C is irrelevant to renal impairment. Option D is a safety concern but not the
most critical pharmacokinetic factor for drug selection in this context.
12 A researcher is designing a study to compare the efficacy of two antihypertensive drugs. To minimize bias, the
study will be double-blind. Which strategy best ensures that the blinding is maintained throughout the trial?
A) Using identical placebo tablets for both drugs and all participants receive both active drugs in a crossover
design.
B) Encapsulating the active drugs and placebo in identical capsules, and having a third party prepare the
randomization code.
C) Administering the drugs intravenously to avoid differences in taste or appearance.
D) Informing participants of the possible side effects of each drug to enhance reporting accuracy.
Answer: B
Rationale: Double-blind means neither participants nor investigators know treatment allocation. Encapsulating drugs
in identical capsules and using a third-party randomization code preserves blinding. Option A is incorrect because a
crossover design doesn't guarantee blinding (participants might receive both drugs sequentially, potentially
